What are the side effects of SS-31 (Elamipretide / MTP-131)?
The most commonly reported SS-31 (Elamipretide / MTP-131) side effects are generally well tolerated, injection-site irritation, rare: headache. Most are mild and tend to be dose dependent. It is generally avoided with pregnancy / nursing. Human clinical evidence for SS-31 (Elamipretide / MTP-131) is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported SS-31 (Elamipretide / MTP-131) side effects
- Generally well tolerated
- Injection-site irritation
- Rare: headache
Who should avoid it
- Pregnancy / nursing
- No data in active malignancy
References
- Elamipretide in primary mitochondrial myopathy (MMPOWER trials) — Karaa A et al., Neurology, 2018
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER — Thompson WR, Manuel R, Abbruscato A, et al. — Genetics in Medicine, 2024
- FORZINITY (elamipretide hydrochloride) injection — FDA Prescribing Information — FDA / DailyMed (Stealth BioTherapeutics), 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on SS-31 (Elamipretide / MTP-131)
Full SS-31 (Elamipretide / MTP-131) breakdownSS-31 (Elamipretide / MTP-131) what it's used forSS-31 (Elamipretide / MTP-131) how to take itSS-31 (Elamipretide / MTP-131) mistakes to avoidSS-31 (Elamipretide / MTP-131) who should avoid itSS-31 (Elamipretide / MTP-131) half-lifeSS-31 (Elamipretide / MTP-131) how long to workSS-31 (Elamipretide / MTP-131) legal statusSS-31 (Elamipretide / MTP-131) how it worksAsk the AI Coach
Last updated 2026-06-15.